ANTICANCER RNA VACCINES Russian patent published in 2022 - IPC A61K31/7088 A61K35/00 

FIELD: medicine; pharmaceutics.

SUBSTANCE: group of inventions relates to cancer vaccines. Anticancer mRNA vaccine contains a lipid nanoparticle containing one or more mRNA with open reading frames, coding 1–500 peptide epitopes — personalized cancer antigens, and type II universal T-cell epitope; one or more mRNA with an open reading frame encoding a peptide of an activating oncogene mutation; one or more mRNA with an open reading frame encoding a peptide epitope of a cancer antigen, wherein the mRNA vaccine encodes 5–100 peptide epitopes and at least two of the peptide epitopes — personalized cancer antigens; and/or one or more mRNA with an open reading frame encoding a peptide epitope of a cancer antigen, wherein the mRNA vaccine encodes 5–100 peptide epitopes, and at least three of the peptide epitopes are complex versions, and at least two of the peptide epitopes are point mutations; wherein the lipid nanoparticle contains 20–60 % ionisable aminolipid, 5–25 % neutral lipid, 25–55 % sterol and 0.5–15 % PEG-modified lipid. Other versions of the anticancer mRNA vaccine, a method of vaccinating a subject, a method of producing mRNA are also disclosed.

EFFECT: group of inventions provides an enhanced immune response.

136 cl, 21 dwg, 10 tbl, 8 ex